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Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically
affects young adults, causing irreversible physical disability and cognitive impairment.
Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5
consecutive days at baseline, and 3 consecutive days 12 months later), resulted in
significantly greater improvements in clinical and MRI outcomes vs. subcutaneous
interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS)
who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate
response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab
was maintained over 7 years in subsequent extension studies (NCT00930553;
NCT02255656), in the absence of continuous treatment and with a consistent safety
profile. There is an increased incidence of autoimmune events in patients treated
with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and
nephropathy), which imparts a need for mandatory safety monitoring for 4 years following
the last treatment. The risk management strategy for alemtuzumab-treated patients
includes laboratory monitoring and a comprehensive patient education and support
program that enables early detection and effective management of autoimmune events,
yielding optimal outcomes for MS patients. Here we provide an overview of tools and
techniques that have been implemented in real-world clinical settings to reduce the
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burden of monitoring for both patients and healthcare providers, including customized
educational materials, the use of social media, and interactive online databases for
managing healthcare data. Many practices are also enhancing patient outreach efforts
through coordination with specialized nursing services and ancillary caregivers. The
best practice recommendations for safety monitoring described in this article, based on
experiences in real-world clinical settings, may enable early detection and management
of autoimmune events, and help with implementation of monitoring requirements while
maximizing the benefits of alemtuzumab treatment for MS patients.
Keywords: relapsing-remitting multiple sclerosis, disease-modifying therapy, alemtuzumab, anti-CD52
monoclonal antibody, monitoring, autoimmune events, best practices, real-world settings
INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune neurological
disease that is the leading cause of disability in young
adults (1). It is frequently characterized by relapses and
remissions with variable sequelae, which may persist and
contribute to progressive and irreversible long-term disability
(2). The underlying pathology of MS is typically marked
by acute lymphocytic inflammation that leads to neuronal
demyelination, neurodegeneration, axonal damage, and to the
eventual formation of lesions within the central nervous system
(3, 4). Alemtuzumab is a humanized anti-CD52 monoclonal
antibody approved for the treatment of patients with active
relapsing-remitting MS (RRMS) defined by clinical or imaging
features. It is administered as intravenous infusions of 2 courses
of 12 mg/day on 5 consecutive days at baseline, and on 3
consecutive days 12 months later (5, 6). In Australia and the
European Union, 2 additional courses may be given as needed for
clinical and MRI activity (3 consecutive days, ≥12 months after
the prior course) (6, 7). The efficacy and safety of alemtuzumab
were established in 3 rater-blinded, comparative clinical trials in
patients who were either treatment-naive (phase 2 CAMMS223;
NCT00050778; and phase 3 Comparison of Alemtuzumab and
Rebif Efficacy inMultiple Sclerosis [CARE-MS] I; NCT00530348)
(8, 9) or had an inadequate response to prior therapy (phase 3
CARE-MS II; NCT00548405) (10).
Alemtuzumab significantly reduced relapses compared with
subcutaneous interferon beta-1a (p < 0.001 in all 3 clinical trials)
and improved disability over 2 years (p < 0.001, and p = 0.008
in the CAMMS223, and CARE-MS II trials, respectively). In
extension studies (NCT00930553, NCT02255656 [TOPAZ]), the
efficacy of alemtuzumab was maintained over at least 7 years,
with many patients (61% from CARE-MS I and 52% from
CARE-MS II) receiving no additional courses of alemtuzumab
(11–15). Although the exact mechanism of action has not
been fully elucidated, alemtuzumab efficacy may be due to
the selective depletion and distinct pattern of repopulation of
circulating CD52-expressing T and B lymphocytes (16, 17).
During repopulation, there is a relative increase in regulatory
T cells which results in a shift from pro- to anti-inflammatory
cytokine profiles driven by differential reconstitution of T-cell
subsets, potentially leading to a rebalancing of the immune
system (18–20). Increased secretion of neurotrophic factors by
the regenerating immune cells may have a neuroprotective effect,
and provide an explanation, at least in part, for the sustained
disability improvements in alemtuzumab-treated patients (21).
The most common adverse events (AEs) associated with
alemtuzumab are infusion-associated reactions and infections,
with the highest rates occurring after the first treatment course
and declining thereafter (13). Alemtuzumab is also associated
with an increased risk for autoimmune events, including thyroid
disease, immune thrombocytopenia (ITP), and nephropathies,
which can manifest months to years after treatment. Table 1
shows the incidence of these events in the clinical development
program and in postmarketing surveillance, suggesting that
the incidence is not higher in real-world settings. Because
of the potential for these autoimmune events, alemtuzumab
is only available through the Risk Evaluation and Mitigation
Strategy program in the United States and Canada, and
the Risk Management Program in Europe (25, 26). These
programs include monthly urinalysis and blood testing for renal
and hematological monitoring, and quarterly thyroid function
monitoring for 48 months after the last alemtuzumab infusion,
as well as physician and patient education about signs and
symptoms of these autoimmune events.
Monitoring can be challenging in clinical practice. As such,
various monitoring tools and techniques have been developed in
real-world clinical settings that may help to reduce the burden
of monitoring and maximize the treatment benefit for patients
receiving alemtuzumab. Although resources and strategies for
patient management vary within individual practices in different
countries, this article aims to provide an overview of these tools
and techniques and offers perspectives from MS clinicians in
various clinical settings on best practices to optimize patient care.
Strategies and Tools to Assist With
Monitoring Alemtuzumab-Treated Patients
in the Clinic
Pre-treatment Preparation
Patient selection
A patient’s commitment to adhere to the risk management
program, including the level of cognitive function and ability
to understand treatment benefits vs. risks, should be considered
before initiating treatment with alemtuzumab. The decision
to initiate alemtuzumab treatment should be made only after
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TABLE 1 | Clinical trial incidence, post-marketing frequency, and signs and symptoms of key autoimmune events after treatment with alemtuzumab.
Key autoimmune
AEa
Incidence in clinical development program
(alemtuzumab 12-mg treatment arm) (13)
Estimated frequency in
post-marketing settingsb (22)
Signs and symptoms
Thyroid events 42c Not available Overactive thyroid: diaphoresis, unexplained weight loss,
eye swelling, nervousness, tachycardia
Underactive thyroid: unexplained weight gain, feeling
cold, increased fatigue, newly occurring constipation
Immune
thrombocytopenia
2.0d 0.72 Bruising, petechiae, purpura, mucosal bleeding,
increased menses, hematuria, melena
Nephropathy 0.27 0.17 Blood in the urine (urine may be red or tea-colored),
swelling in legs and feet, hemoptysis
aDoes not include other rare autoimmune AEs (e.g., alopecia, acquired hemophilia A) that have been reported in alemtuzumab-treated patients (23, 24).
bCalculated as number of cases/total number of patients (n = 18,561) treated through December 31, 2017.
cOver 6 years in the pooled CARE-MS patients who received alemtuzumab 12mg (n = 811).
dOver 5 years of total follow-up for CARE-MS studies and 8 years for CAMMS223 study in patients who received alemtuzumab 12mg (n = 1,217).
AE, adverse event; CARE-MS, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis.
ensuring that patients understand the need for long-term
monitoring, and/or if patients have family and community
support to help comply with monitoring.
Patient education and lifestyle management
The benefits of patient education and engagement in the
management of MS are well documented (27–30). National
Institute for Clinical Excellence guidelines and the European
MS Platform’s Code of Good Practice recommend implementing
an education program that incorporates information about the
disease, and provides guidance on the level of communication
and emotional support while encouraging patient autonomy/self-
management (31, 32). The MS Brain Health initiative, which
emerged from an evidence-based international consensus report
(33), recommends a “brain-healthy” lifestyle as part of a
comprehensive approach to treatment and management of
MS. Given that cardiovascular fitness correlates with brain
volume and cognitive reserve (34), patients should be advised
to incorporate aerobic exercise into their daily routines.
They should also be encouraged to stop smoking to prevent
excessive reduction in brain volume and worsening of disability
progression (35–37), and to limit the use of alcohol to help
maintain and maximize lifelong brain health.
As soon as the decision has been made to initiate treatment
with alemtuzumab, patients receive various educational materials
provided by the drug manufacturer, including a patient
handbook that contains information on support services,
treatment, and monitoring (Figures 1A,B). Patients are educated
about the signs and symptoms of potential thyroid disorders,
ITP, and nephropathies, and are given images of relevant
AEs for visual reference (e.g., Figure 1C). Patients are also
provided with an alert card containing helpful information
for their regular and emergency healthcare providers (HCPs)
(Figure 1D), which is particularly important if after-hours
care is not available in the prescribing physician’s office.
In addition to educational materials provided by the drug
manufacturer, clinical practices may consider developing their
own information packages, as appropriate, including the use of
social media (e.g., YouTube), highlighting the treatment benefits
and potential side effects. However, as the veracity of online
material is variable, scrutiny before recommending various
platforms is pertinent.
It is crucial for HCPs to discuss the importance of monitoring
with patients, as some patients may not understand the need to
continue monitoring for an extended period after the completion
of the active treatment phase. HCPs should emphasize that
monitoring is for the benefit of the patient and that it can
help with early detection and management of potential side
effects, thereby ensuring that the positive effects of treatment
are not circumvented. Additionally, HCPs may remind patients
that many of the other MS therapies require daily to monthly
administration, which is avoided with alemtuzumab. Some
clinical practices request patients to sign an informed consent
form, documenting that they have received education about
the benefits and risks of treatment and are aware of their
responsibilities for monitoring and follow-up, whereas other
practices (in the UK and Belgium, for example) mail the
alemtuzumab education materials directly to the patient’s general
practitioner (GP) to help with post-treatment monitoring. Lastly,
patients should be advised to schedule their blood and urine
tests at locations that are most convenient to them, including
outpatient clinics, hospitals, or GPs office (if the latter provides
these services). In some areas, clinical practices can also arrange
for home visits by nursing staff to carry out monthly blood and
urine tests.
Post-treatment Follow-Up
Patient support tools for monitoring
The alemtuzumab patient support program, MS One-to-One,
is available to MS patients and their HCPs in North America,
Europe, and other countries (Table 2) (38). It offers access to a
network of nurses to assist with MS education and information
on alemtuzumab. It also includes a platform for patients to
share their experiences on living with MS, and provides links
to support groups and patient advocacy organizations such as
the MS Association of America and the National MS Society
(39, 40). The MS One-to-One program has been used to
assist with monitoring compliance and follow-up, particularly
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FIGURE 1 | (A) Alemtuzumab dosing regimen and monitoring, (B) patient
monitoring calendar, (C) patient reference guide with examples of immune
thrombocytopenia (ITP) skin conditions, and (D) patient alert card.
in MS clinics with large numbers of alemtuzumab-treated
patients and in neurologists’ offices with limited in-house
support staff.
Many clinics have developed web-based portals that facilitate
communication between the patient and his/her clinical support
team (41). These portals may include patient questionnaires
to self-report new symptoms and disease impact on their
daily quality of life, which in turn may prompt HCP referrals
to other healthcare services. In the UK and other European
countries, clinicians use the Multiple Sclerosis Impact Scale-29,
a 29-item self-report rating scale for measuring the physical and
psychological impact of MS (Table 2) (42, 43). Results from this
online questionnaire are transferred to a web portal that can be
accessed by HCPs within a given geographic area. Asymptomatic
patients who do not need face-to-face consultation are
followed up within 3–6 months. The nursing staff also
conducts “virtual” consultations via Skype or telephone, thus
providing patients with convenient and flexible alternatives to
office visits.
In several European countries, as well as in the United States,
alemtuzumab-treated patients can use smartphone applications
to set up reminders for complying with monthly tests, to identify
the signs and symptoms of side effects through self-check,
and to access MS-related health information (Table 2). HCPs
have begun integrating e-mail and text messaging into their
clinical practices, and are providing online links to tools such
as alemtuzumab monitoring calendars to help patients track
their appointments.
Lemtracks is a web-based, electronic patient reminder
system available to MS centers across Europe that supports
alemtuzumabmonitoring requirements (Table 2). It allowsHCPs
and MS nurses to send appointment reminders to patients and,
importantly, alerts them to missed appointments and abnormal
lab results.
In Belgium, clinical practices request an independent nurse
service (e.g., LemMon) to obtain blood and urine samples from
patients in their homes (Table 2). During their home visits,
nurses educate patients on the importance of routine monitoring
and self-checks for signs and symptoms of AEs. They also report
the occurrence of possible AEs to the MS clinic, and alert the
clinic when patients miss appointments. In the UK, monitoring
nurses are in charge of performing the monthly monitoring
tests in hospitals. If the tests are done in the GP’s clinic, the
monitoring nurses coordinate with the clinic as needed to ensure
timely receipt of laboratory results for evaluation and follow-up.
Other clinical practices in North America and Europe collaborate
with nurses and social workers for follow-up and laboratory
test reminders.
Patient support tools may vary by institution, country, and
local regulations. For example, in Norway, legal regulations
require HCPs to access data only from the patients’ hospital
records, which may limit the use of different methods
for follow-up. Clinical practices would thus benefit from
having dedicated nursing staff adequately trained to care
for patients with MS, assess patient symptoms, detect
potential AEs and abnormal laboratory results, and ensure
careful record-keeping.
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TABLE 2 | Patient support tools for monitoring and follow-up after treatment with alemtuzumab.
Program Country Scope Contact information
MS One-to-One United States
Canada
Various countries in Europe
South Africa
Assists with tracking results and
monitoring compliance
www.msonetoone.com
http://mylemtrada.ca
http://msonetoone.eu
https://msonetoone.co.za/patient/
login#/
MSIS-29 UK A 29-item, patient-reported
questionnaire that assesses the
physical and psychological impact of
MS
https://www.mstrust.org.uk/sites/
default/files/MSIS-29.pdf
Smartphone applications
Examples:
• MSAA’ s My MS ManagerTM
• CareZone
• LEMTRADA® MyLink
• LEMCHECKTM
United States and various
countries in Europe
• Track patients’ monitoring
appointments
• Access online links to
alemtuzumab monitoring calendar
• Provide information on signs and
symptoms of autoimmune AEs
• Send e-mail/text reminders to:
ãComply with monthly tests (e.g.,
blood and urine)
ãSelf-check for signs and
symptoms of AEs
Share findings with HCPs
Lemtracks (“Your Lemtrada” in Italy) Various countries in Europe Assists HCPs and MS nurses with
appointment reminders and sends
alerts for missed appointments and
abnormal test results
LemMon Belgium Obtains blood and urine samples
from patients in their homes
http://www.remedus.be/nl
AE, adverse event; HCP, healthcare provider; MSAA, Multiple Sclerosis Association of America; MSIS-29, Multiple Sclerosis Impact Scale-29.
Patient support tools for management of laboratory test data
Several MS-specific networks and databases are available that
can facilitate patient data management (44–47). The MS-
Documentation System: 3-Dimensional—Physicians, Nurses,
and Patients (MSDS3D) (48, 49) is a widely used electronic
management system for MS patients in Germany that can
integrate data generated by physicians, nurses, and patients
(Figure 2). Laboratory data collected from different sites can
be transmitted to a central service for automatic processing.
The MSDS3D platform also allows post-treatment monitoring
of routine blood tests and immunologic samples, sending
automatic e-mail notifications to HCPs. Patients’ results are
displayed in a progression graphic, providing a long-term
overview of their condition. Other functionalities of the MSDS3D
system include clinical advice on difficult cases from experts
who have restricted access to patient MRI data from external
MRI reading centers, and collection of post-authorization
safety data (50).
An MSDS3D module for patients treated with alemtuzumab
is currently being used in the TREAT-MS study (49). It
is designed to connect all the HCPs responsible for the
individual MS patient and enable comprehensive healthcare
management by capturing patient data from the time of
the last alemtuzumab treatment. Based on the patient data,
MSDS3D generates prospective checklists for physicians and
patients before treatment initiation. These checklists would
guide and facilitate the next steps in the treatment schedule,
including generating health forms for insurance purposes. The
structured interface of the MSDS3D system can potentially
support physicians and nurses to monitor alemtuzumab-treated
patients effectively.
Many clinics across Australia use an automated clinical
decision support system to implement the risk management
program for MS patients treated with alemtuzumab (51). This
computerized system is designed to track the pathology reports
of alemtuzumab-treated patients and provide customizable alerts
for abnormalities in identified risks.
In Canada, some clinical practices are using an automated,
integrated, healthcare data management system developed
by ExcellerisTM Technologies (52) to monitor patients after
treatment with alemtuzumab. Excelleris is a medical platform
that standardizes health information from various sources and
transmits laboratory data to clinicians. Building on this medical
platform, clinicians have developed an automated alert program
for ensuring compliance with monitoring monthly tests and
screening for autoimmune events specific to alemtuzumab-
treated patients. The platform is designed to harvest laboratory
results, regardless of the laboratory location or the prescribing
physician, and immediately trigger e-mail/text alerts for both
clinicians and patients if a significant abnormality is identified
within the program’s parameters. This alemtuzumab automated
alert platform contains other features that facilitate monitoring
and follow-up, including a clinician portal that compiles patient
information, graphs and analyzes test results and/or patterns over
Frontiers in Neurology | www.frontiersin.org 5 March 2019 | Volume 10 | Article 253
Barclay et al. Long-Term Monitoring With Alemtuzumab
FIGURE 2 | MSDS3D patient data management system. Reprinted from Ziemssen et al. (49). Creative Commons Attribution 4.0 International Public License.
FIGURE 3 | The Remedus data management platform.
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FIGURE 4 | Overview of the laboratory testing plan for autoimmune disorder risk monitoring. aApproximately 10% decrease in 3 successive measurements or >30%
decrease from previous month or reticulated platelet count is above normal; bPlatelet count <50 × 109/L. T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating
hormone; TSH-R, thyroid-stimulating hormone-receptor; ER, emergency room.
time, identifies the infusion dates, and allows communication
between HCPs within the portal to respond to AEs.
Remedus is an online platform used in MS clinical practices
across Belgium to communicate laboratory test results to HCPs
(a neurologist or a GP) in real-time (Figure 3) (53). The database
stores patient data along with the date of testing, and generates
reports for HCPs every 3 months. Any abnormal result or delay
in patient compliance triggers an alert for HCPs, allowing them
to follow up with the patient.
Addressing Patient Non-compliance
In real-world clinical settings, even with the implementation
of best practices for monitoring, some patients may not be
compliant. Alemtuzumab-treated patients who do not have any
evidence of disease activity and have not received additional
treatment since their initial 2 courses of alemtuzumab, may
be at particular risk for non-compliance with monitoring.
Additionally, patients may become worn out by the requirement
for frequent blood draws. Cognitive deficits and loss of family
support may also contribute to non-compliance.
If a patient becomes non-compliant, HCPs and the nursing
staff should take steps to determine an acceptable solution
to re-establish compliance. This may include in-home lab
collection, personal follow-up, seeking assistance from patient’s
GP and family members/community, tailoring reminder systems
to suit the patient’s lifestyle, and reiterating the importance of
monitoring, while highlighting the treatment benefits vs. risks.
Practical Guidance for Management of
Autoimmune Events
A recent task force of MS specialists, hematologists,
nephrologists, and endocrinologists from Belgium issued
practical recommendations on the management and daily
clinical care of patients in the event of abnormal findings
following treatment with alemtuzumab (Figure 4) (54–56). In
patients with thyroid dysfunction associated with alemtuzumab
treatment, a watch-and-wait approach is recommended if
thyroid-stimulating hormone levels increase but free thyroxine
(T4) levels remain normal, with testing every 6 weeks (54).
In case of elevated thyroid-stimulating hormone, if free T4 is
decreased, or if symptoms/signs of hypothyroidism are present,
or if baseline serum thyroperoxidase antibody status is positive,
treatment with synthetic T4 is indicated. In case of increased
free T4 (>1.5-fold the upper limit of normal) or symptoms/signs
of hyperthyroidism, symptomatic treatment with propranolol
should be started.
In patients with clinical signs suggestive of bleeding
after alemtuzumab, a complete blood count (CBC) must
be obtained immediately (55). Any steep decrease of 50%
or more from previous value but still above 100,000/µL
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must prompt an immediate recheck of the CBC to exclude
pseudothrombocytopenia (platelet aggregates), with a referral to
the hematologist if ITP is confirmed. A CBC between 30,000 and
100,000/µL and no bleeding symptoms should prompt a recheck
within 48–72 h, and a hematologist should be contacted to discuss
referral. Active bleeding or platelet count below 10,000/µL make
treatment mandatory.
Isolated microscopic hematuria can be an initial sign
of alemtuzumab-related anti-glomerular basement membrane
disease (56). Weekly urinalysis is recommended to check
for isolated or persistent hematuria. Isolated gross hematuria
with urine discoloration must be reported immediately to the
patient’s neurologist or GP for follow-up blood and urine
testing. Persistent hematuria must prompt a referral to a
routine nephrology consultancy as soon as possible to test for
anti-glomerular basement membrane antibodies. An immediate
referral to a nephrologist is warranted in case of persistent
hematuria with increased serum creatinine. A proteinuria finding
above 0.2 grams protein per gram of creatinine needs further
investigation, with referral to a nephrologist for a non-urgent
consultation once urinary tract infection is excluded.
DISCUSSION
Effective disease management of chronic conditions such as MS
requires a collaborative approach between HCPs and patients,
and a multidisciplinary team of support staff. Treatment with
alemtuzumab has been shown to reduce relapse rates, improve
disability, and decrease MRI lesion activity and brain volume
loss in patients with active RRMS over at least 7 years, with
many patients receiving no additional alemtuzumab courses
or other disease-modifying therapies (11–15). Improvements in
disability are associated with improvements in patients’ quality
of life and work productivity, and decreases in healthcare
costs (57, 58).
However, these benefits are associated with potential side
effects. There is an increased risk for autoimmune events in
patients treated with alemtuzumab (mainly thyroid events,
but also ITP and nephropathies), which requires a specific
monitoring regimen. These events can be managed if diagnosed
early. AEs with other disease-modifying therapies have
associated risks that remain constant or even increase with
repeated exposure to drug (59–61). Other rare autoimmune side
effects (e.g., alopecia, acquired hemophilia A, and neutropenia)
have also been reported in patients treated with alemtuzumab
(23, 24, 62). Implementing a comprehensive management
program may improve outcomes in patients treated with
alemtuzumab and maximize the therapeutic benefit as shown
by the consistent safety profile in patients with active RRMS
over 7 years (14, 15). Recent publications have outlined practical
recommendations for managing these autoimmune events after
alemtuzumab through careful analysis of monthly laboratory
results (54–56, 63).
Several tools and strategies have been developed to implement
the monitoring requirements and follow-up of patients treated
with alemtuzumab. The use of educational materials through
verbal reinforcement and support from physicians and nursing
staff, via online tools, and through coordination with ancillary
caregivers will increase patients’ understanding of treatment
benefits and risks.
Specialized nursing services that can facilitate
interdisciplinary care have been beneficial, along with the
use of online technologies, social media, and electronic health
records and databases for management of laboratory results and
patient data. These databases also enable access to patient data in
real-time, which helps HCPs make informed clinical decisions.
Sustained patient outreach efforts and patient engagement
by caregivers, including social workers, may improve patient
adherence to monitoring, improve coping skills, and have a
positive impact on patients’ overall quality of life. The best
practice recommendations described in this article are based
on experiences in the real-world clinical settings, and may help
reduce the burden of monitoring for both patients and HCPs and
maximize the benefits in MS patients while minimizing the risks
of treatment with alemtuzumab.
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